Long-term safety and cognitive effects of @entity11545 in the treatment of probable @entity1294 or @entity195 with XXXX .

@entity1 @entity308 @entity66 @entity303 @entity73 @entity1294 @entity409 @entity11545 @entity2146 @entity195 @entity22
The relationship between @entity409 and @entity73 in @entity1 with @entity1294 ( @entity1294 ) and @entity195 ( @entity195 ) with @entity66 ( @entity66 ) suggests a potential role for cholinomimetic therapy. Initial studies of @entity11545 demonstrated cognitive, behavioral, and functional benefits in these populations. 326 @entity1 with @entity1294 or @entity195 with @entity66 who completed an initial 12-month trial were treated with @entity11545 24 mg/day in a 24-month, open-label extension. This interim analysis was performed at month 12 of the open-label extension (248 completed the trial). @entity11545 (up to 24 months total) was well tolerated in both groups. The most frequently reported adverse events, characteristic of older @entity303 @entity1 , included @entity308 , @entity2146 , and @entity22 . Gastrointestinal adverse events were less common than initially, indicating declining incidence with long-term therapy. @entity1 taking @entity11545 for the entire study demonstrated the least @entity73 on @entity195 Assessment Scale-cog/11: 2.7 points vs. 3.1 points in those given placebo initially (P < 0.001 and P = 0.003, respectively). The long-term benefits of @entity11545 were evident in both groups; cognitive baseline levels were maintained for approximately 21 months in @entity1294 @entity1 and for 12 months in @entity1 with @entity195 with @entity66 . Long-term (up to 24 months) @entity11545 therapy in @entity1 with @entity1294 and @entity195 with @entity66 is well tolerated and associated with prolonged maintenance of cognitive function.
